Tropomyosins: potential biomarkers for Urothelial Bladder Cancer

Research output: Contribution to journalReview article

Authors

Colleges, School and Institutes

Abstract

Despite the incidence and prevalence of urothelial bladder cancer (UBC), few advances in treatment and diagnosis have been made in recent years. In this review, we discuss potential biomarker candidates: the tropomyosin family of genes, encoded by four loci in the human genome. The expression of these genes is tissue-specific. Tropomyosins are responsible for diverse cellular roles, most notably based upon their interplay with actin to maintain cellular processes, integrity and structure. Tropomyosins exhibit a large variety of splice forms, and altered isoform expression levels have been associated with cancer, including UBC. Notably, tropomyosin isoforms are detectable in urine, offering the potential for non-invasive diagnosis and risk-stratification. This review collates the basic knowledge on tropomyosin and its isoforms, and discusses their relationships with cancer-related phenomena, most specifically in UBC

Details

Original languageEnglish
Article number1102
Number of pages14
JournalInternational Journal of Molecular Sciences
Volume20
Issue number5
Publication statusPublished - 4 Mar 2019

Keywords

  • tropomyosin, TPM, urothelial bladder cancer, NMIBC